AstraZeneca and Daiichi Sankyo's ADC cancer drug approved for fifth indication in China.

According to AstraZeneca, its injection drug pertuzumab has been approved for a fifth new indication in China, as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor-positive HER2-low expression or HER2-ultra-low expression breast cancer who have progressed following one or more prior endocrine therapies in the metastatic setting. This drug becomes the first HER2-targeted therapy for patients with HER2-low or ultra-low expression breast cancer who have progressed following one or more prior endocrine therapies in the metastatic setting.